A bacteriocin expression platform for targeting pathogenic bacterial species.
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
27 Jul 2024
27 Jul 2024
Historique:
received:
21
11
2023
accepted:
16
07
2024
medline:
28
7
2024
pubmed:
28
7
2024
entrez:
27
7
2024
Statut:
epublish
Résumé
Bacteriocins are antimicrobial peptides that are naturally produced by many bacteria. They hold great potential in the fight against antibiotic resistant bacteria, including ESKAPE pathogens. Engineered live biotherapeutic products (eLBPs) that secrete bacteriocins can be created to deliver targeted bacteriocin production. Here we develop a modular bacteriocin secretion platform that can be used to express and secrete multiple bacteriocins from non-pathogenic Escherichia coli host strains. As a proof of concept we create Enterocin A (EntA) and Enterocin B (EntB) secreting strains that show strong antimicrobial activity against Enterococcus faecalis and Enterococcus faecium in vitro, and characterise this activity in both solid culture and liquid co-culture. We then develop a Lotka-Volterra model that can be used to capture the interactions of these competitor strains. We show that simultaneous exposure to EntA and EntB can delay Enterococcus growth. Our system has the potential to be used as an eLBP to secrete additional bacteriocins for the targeted killing of pathogenic bacteria.
Identifiants
pubmed: 39068147
doi: 10.1038/s41467-024-50591-8
pii: 10.1038/s41467-024-50591-8
doi:
Substances chimiques
Bacteriocins
0
Anti-Bacterial Agents
0
enterocin A
0
enterocin B
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6332Subventions
Organisme : RCUK | Engineering and Physical Sciences Research Council (EPSRC)
ID : EP/W004674/1
Organisme : RCUK | Engineering and Physical Sciences Research Council (EPSRC)
ID : EP/X026892/1
Organisme : RCUK | Engineering and Physical Sciences Research Council (EPSRC)
ID : EP/W004674/1
Organisme : RCUK | Engineering and Physical Sciences Research Council (EPSRC)
ID : EP/W004674/1
Organisme : RCUK | Medical Research Council (MRC)
ID : MR/W025655/1
Informations de copyright
© 2024. The Author(s).
Références
Bai, X. et al. Engineering the gut microbiome. Nat. Rev. Bioeng. 1, 665–679 (2023).
doi: 10.1038/s44222-023-00072-2
Riglar, D. T. & Silver, P. A. Engineering bacteria for diagnostic and therapeutic applications. Nat. Rev. Microbiol. 16, 214–225 (2018).
pubmed: 29398705
doi: 10.1038/nrmicro.2017.172
Zhou, Z. et al. Engineering probiotics as living diagnostics and therapeutics for improving human health. Microb. Cell Factories 19, 56 (2020).
doi: 10.1186/s12934-020-01318-z
Charbonneau, M. R., Isabella, V. M., Li, N. & Kurtz, C. B. Developing a new class of engineered live bacterial therapeutics to treat human diseases. Nat. Commun. 11, 1738 (2020).
pubmed: 32269218
pmcid: 7142098
doi: 10.1038/s41467-020-15508-1
Ozdemir, T., Fedorec, A. J., Danino, T. & Barnes, C. P. Synthetic biology and engineered live biotherapeutics: Toward increasing system complexity. Cell Syst. 7, 5–16 (2018).
pubmed: 30048620
doi: 10.1016/j.cels.2018.06.008
Rutter, J. W., Dekker, L., Owen, K. A. & Barnes, C. P. Microbiome engineering: engineered live biotherapeutic products for treating human disease. Front. Bioeng. Biotechnol. 10, 1000873 (2022).
pubmed: 36185459
pmcid: 9523163
doi: 10.3389/fbioe.2022.1000873
Oromí-Bosch, A., Antani, J. D. & Turner, P. E. Developing phage therapy that overcomes the evolution of bacterial resistance. Annu. Rev. Virol. 10, 503–524 (2023).
pubmed: 37268007
doi: 10.1146/annurev-virology-012423-110530
Moretta, A. et al. Antimicrobial peptides: A new hope in biomedical and pharmaceutical fields. Front. Cell. Infect. Microbiol. 11, 668632 (2021).
pubmed: 34195099
pmcid: 8238046
doi: 10.3389/fcimb.2021.668632
Cotter, P. D., Ross, R. P. & Hill, C. Bacteriocins - a viable alternative to antibiotics? Nat. Rev. Microbiol. 11, 95–105 (2013).
pubmed: 23268227
doi: 10.1038/nrmicro2937
Meade, E., Slattery, M. A. & Garvey, M. Bacteriocins, potent antimicrobial peptides and the fight against multi drug resistant species: Resistance is futile? Antibiotics 9, 32 (2020).
pubmed: 31963311
pmcid: 7168330
doi: 10.3390/antibiotics9010032
Simons, A., Alhanout, K. & Duval, R. E. Bacteriocins, antimicrobial peptides from bacterial origin: Overview of their biology and their impact against multidrug-resistant bacteria. Microorganisms 8, 639 (2020).
pubmed: 32349409
pmcid: 7285073
doi: 10.3390/microorganisms8050639
Kjos, M. et al. Target recognition, resistance, immunity and genome mining of class ii bacteriocins from gram-positive bacteria. Microbiology 157, 3256–3267 (2011).
pubmed: 21980118
doi: 10.1099/mic.0.052571-0
Negash, A. W. & Tsehai, B. A. Current Applications of Bacteriocin. Int. J. Microbiol. 2020, 4374891 (2020).
pubmed: 33488719
pmcid: 7803181
doi: 10.1155/2020/4374891
Pircalabioru, G. G. et al. Bacteriocins in the era of antibiotic resistance: Rising to the challenge. Pharmaceutics 13, 196 (2021).
doi: 10.3390/pharmaceutics13020196
Soltani, S. et al. Bacteriocins as a new generation of antimicrobials: toxicity aspects and regulations. FEMS Microbiol. Rev. 45, fuaa039 (2021).
pubmed: 32876664
doi: 10.1093/femsre/fuaa039
Mirzadeh, K. et al. Increased production of periplasmic proteins in Escherichia coli by directed evolution of the translation initiation region. Microb. Cell Factories 19, 85 (2020).
doi: 10.1186/s12934-020-01339-8
Grasso, S. et al. Signal peptide efficiency: From high-throughput data to prediction and explanation. ACS Synth. Biol. 12, 390–404 (2023).
pubmed: 36649479
pmcid: 9942255
doi: 10.1021/acssynbio.2c00328
Wu, Z. et al. Signal peptides generated by attention-based neural networks. ACS Synth. Biol. 9, 2154–2161 (2020).
pubmed: 32649182
doi: 10.1021/acssynbio.0c00219
Freudl, R. Signal peptides for recombinant protein secretion in bacterial expression systems. Microb. Cell Factories 17, 52 (2018).
doi: 10.1186/s12934-018-0901-3
Gupta, S., Bram, E. E. & Weiss, R. Genetically programmable pathogen sense and destroy. ACS Synth. Biol. 2, 715–723 (2013).
pubmed: 23763381
doi: 10.1021/sb4000417
Borrero, J., Chen, Y., Dunny, G. M. & Kaznessis, Y. N. Modified lactic acid bacteria detect and inhibit multiresistant enterococci. ACS Synth. Biol. 4, 299–306 (2015).
pubmed: 24896372
doi: 10.1021/sb500090b
Geldart, K., Borrero, J. & Kaznessis, Y. N. Chloride-inducible expression vector for delivery of antimicrobial peptides targeting antibiotic-resistant Enterococcus faecium. Appl. Environ. Microbiol. 81, 3889–3897 (2015).
pubmed: 25841002
pmcid: 4421067
doi: 10.1128/AEM.00227-15
Geldart, K., Forkus, B., McChesney, E., McCue, M. & Kaznessis, Y. pMPES: a modular peptide expression system for the delivery of antimicrobial peptides to the site of gastrointestinal infections using probiotics. Pharmaceuticals 9, 60 (2016).
pubmed: 27782051
pmcid: 5198035
doi: 10.3390/ph9040060
Geldart, K. G. et al. Engineered E. coli nissle 1917 for the reduction of vancomycin-resistant Enterococcus in the intestinal tract. Bioeng. Transl. Med. 3, 197–208 (2018).
pubmed: 30377660
pmcid: 6195901
doi: 10.1002/btm2.10107
de Almeida, C. V., Taddei, A. & Amedei, A. The controversial role of Enterococcus faecalis in colorectal cancer. Therapeutic Adv. Gastroenterol. 11, 175628481878360 (2018).
doi: 10.1177/1756284818783606
Balamurugan, R., Rajendiran, E., George, S., Samuel, G. V. & Ramakrishna, B. S. Real-time polymerase chain reaction quantification of specific butyrate-producing bacteria, Desulfovibrio and Enterococcus faecalis in the feces of patients with colorectal cancer. J. Gastroenterol. Hepatol. 23, 1298–1303 (2008).
pubmed: 18624900
doi: 10.1111/j.1440-1746.2008.05490.x
Huycke, M. M., Abrams, V. & Moore, D. R. Enterococcus faecalis produces extracellular superoxide and hydrogen peroxide that damages colonic epithelial cell dna. Carcinogenesis 23, 529–536 (2002).
pubmed: 11895869
doi: 10.1093/carcin/23.3.529
Wang, X., Yang, Y. & Huycke, M. M. Commensal-infected macrophages induce dedifferentiation and reprogramming of epithelial cells during colorectal carcinogenesis. Oncotarget 8, 102176–102190 (2017).
pubmed: 29254234
pmcid: 5731944
doi: 10.18632/oncotarget.22250
Viljoen, K. S., Dakshinamurthy, A., Goldberg, P. & Blackburn, J. M. Quantitative profiling of colorectal cancer-associated bacteria reveals associations between fusobacterium spp., enterotoxigenic bacteroides fragilis (etbf) and clinicopathological features of colorectal cancer. PLOS ONE 10, e0119462 (2015).
pubmed: 25751261
pmcid: 4353626
doi: 10.1371/journal.pone.0119462
Grootaert, C. et al. Bacterial monocultures, propionate, butyrate and h2o2 modulate the expression, secretion and structure of the fasting-induced adipose factor in gut epithelial cell lines. Environ. Microbiol. 13, 1778–1789 (2011).
pubmed: 21518214
doi: 10.1111/j.1462-2920.2011.02482.x
Mathur, H. et al. Bacteriocin-antimicrobial synergy: A medical and food perspective. Front. Microbiol. 8, 01205 (2017).
doi: 10.3389/fmicb.2017.01205
Arias, C. A., Mendes, R. E., Stilwell, M. G., Jones, R. N. & Murray, B. E. Unmet needs and prospects for oritavancin in the management of vancomycin-resistant enterococcal infections. Clin. Infect. Dis. 54, S233–S238 (2012).
pubmed: 22431854
pmcid: 6279151
doi: 10.1093/cid/cir924
Mulani, M. S., Kamble, E. E., Kumkar, S. N., Tawre, M. S. & Pardesi, K. R. Emerging strategies to combat eskape pathogens in the era of antimicrobial resistance: A review. Front. Microbiol. 10, 00539 (2019).
doi: 10.3389/fmicb.2019.00539
Iverson, S. V., Haddock, T. L., Beal, J. & Densmore, D. M. Cidar moclo: Improved moclo assembly standard and new E. coli part library enable rapid combinatorial design for synthetic and traditional biology. ACS Synth. Biol. 5, 99–103 (2016).
pubmed: 26479688
doi: 10.1021/acssynbio.5b00124
Shi, L., Liu, H., Gao, S., Weng, Y. & Zhu, L. Enhanced extracellular production of Ispetase in Escherichia coli via engineering of the pelb signal peptide. J. Agric. Food Chem. 69, 2245–2252 (2021).
pubmed: 33576230
doi: 10.1021/acs.jafc.0c07469
Teufel, F. et al. Signalp 6.0 predicts all five types of signal peptides using protein language models. Nat. Biotechnol. 40, 1023–1025 (2022).
pubmed: 34980915
pmcid: 9287161
doi: 10.1038/s41587-021-01156-3
Fedorec, A. J. H., Robinson, C. M., Wen, K. Y. & Barnes, C. P. Flopr: an open source software package for calibration and normalization of plate reader and flow cytometry data. ACS Synth. Biol. 9, 2258–2266 (2020).
pubmed: 32854500
pmcid: 7506944
doi: 10.1021/acssynbio.0c00296
Momeni, B., Xie, L. & Shou, W. Lotka-volterra pairwise modeling fails to capture diverse pairwise microbial interactions. Elife 6, e25051 (2017).
pubmed: 28350295
pmcid: 5469619
doi: 10.7554/eLife.25051
Choi, J. H. & Lee, S. Y. Secretory and extracellular production of recombinant proteins using Escherichia coli. Appl. Microbiol. Biotechnol. 64, 625–635 (2004).
pubmed: 14966662
doi: 10.1007/s00253-004-1559-9
Kim, S.-K. et al. Simple amino acid tags improve both expression and secretion of Candida antarctica lipase b in recombinant Escherichia coli. Biotechnol. Bioeng. 112, 346–355 (2015).
pubmed: 25182473
doi: 10.1002/bit.25361
Yang, K. M. et al. Lactobacillus reuteri an417 cell-free culture supernatant as a novel antibacterial agent targeting oral pathogenic bacteria. Sci. Rep. 11, 1631 (2021).
pubmed: 33452304
pmcid: 7810884
doi: 10.1038/s41598-020-80921-x
Casaus, P. et al. Enterocin B, a new bacteriocin from Enterococcus faecium T136 which can act synergistically with enterocin A. Microbiology 143, 2287–2294 (1997).
pubmed: 9245817
doi: 10.1099/00221287-143-7-2287
Ankaiah, D. et al. Cloning, overexpression, purification of bacteriocin enterocin-b and structural analysis, interaction determination of enterocin-a, b against pathogenic bacteria and human cancer cells. Int. J. Biol. Macromol. 116, 502–512 (2018).
pubmed: 29729340
doi: 10.1016/j.ijbiomac.2018.05.002
Ceroni, F., Algar, R., Stan, G.-B. & Ellis, T. Quantifying cellular capacity identifies gene expression designs with reduced burden. Nat. Methods 12, 415–418 (2015).
pubmed: 25849635
doi: 10.1038/nmeth.3339
Benitez-Chao, D. F., Leon-Buitimea, A., Lerma-Escalera, J. A. & Morones-Ramirez, J. R. Bacteriocins: An overview of antimicrobial, toxicity, and biosafety assessment by in vivo models. Front. Microbiol. 12, 630695 (2021).
pubmed: 33935991
pmcid: 8083986
doi: 10.3389/fmicb.2021.630695
da Cunha, N. B. et al. The next generation of antimicrobial peptides (amps) as molecular therapeutic tools for the treatment of diseases with social and economic impacts. Drug Discov. Today 22, 234–248 (2017).
pubmed: 27890668
doi: 10.1016/j.drudis.2016.10.017
Tang, R. et al. Application of antimicrobial peptides in plant protection: making use of the overlooked merits. Front. Plant Sci. 14, 1139539 (2023).
pubmed: 37538059
pmcid: 10394246
doi: 10.3389/fpls.2023.1139539
Liu, Y., Sameen, D. E., Ahmed, S., Dai, J. & Qin, W. Antimicrobial peptides and their application in food packaging. Trends Food Sci. Technol. 112, 471–483 (2021).
doi: 10.1016/j.tifs.2021.04.019
Gabant, P. & Borrero, J. Paragen 1.0: A standardized synthetic gene library for fast cell-free bacteriocin synthesis. Front. Bioeng. Biotechnol. 7, 213 (2019).
pubmed: 31552239
pmcid: 6743375
doi: 10.3389/fbioe.2019.00213
Schindelin, J. et al. Fiji: an open-source platform for biological-image analysis. Nat. Methods 9, 676–682 (2012).
pubmed: 22743772
doi: 10.1038/nmeth.2019